Oslo, Norway, 24 August 2022

Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for
the second quarter and first half 2022 on Wednesday, 31 August 2022.

A presentation by Nordic Nanovector's senior management team will be held in
-person and webcast live beginning at 8:30am CEST.

Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Bjørvika

The webcast can be accessed from www.nordicnanovector.com in the section:
Investors & Media and a recording will also be available on this page after the
event.

The results report and the presentation will be available at
www.nordicnanovector.com in the section: Investors & Media/Reports and
Presentation/Interim Reports/2022 from 7:00am CEST the same day.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)

Tel: +44 203 928 6900

Email: nordicnanovector@medistrava.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in radionuclide therapy of cancer. In
addition to Betalutin®, for which Nordic Nanovector retains global marketing
rights, the Company's novel pipeline includes Humalutin®, a radioimmunotherapy
candidate based on a chimeric anti-CD37 antibody and the beta emitter lutetium
-177 for NHL